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Objectives: The increasing health-care cost of lung cancer treatment has
caused debates regarding the reimbursement of new medications. The
purpose of this study was to estimate patients’ willingness to pay (WTP)
for a hypothetical new drug.
Methods: Patients with lung cancer were recruited through referrals by
senior specialists from two medical centers in Taiwan. Double-bounded
dichotomous choice questions and follow-up open-ended questions were
employed to elicit patients’ WTP. The contingent valuation question
assumed that a novel medication was available, which provided a cure for
lung cancer; however, patients would have to pay for this new cure out of
their own pocket. In addition, the question was asked as to how much
patients would be willing to pay for supplementary hospitalization insur-
ance? Interval regression and linear regression were used to estimate the
maximum WTP.
Results: A total of 294 patients were recruited; their mean age was 67
years; 74% were male and 26% were female. The results show that
patients were prepared to pay New Taiwan dollar (NTD) 7416 or NTD
7032 per month to purchase this new medication. Sex, religion, income,
the Karnofsky Performance Scale score, and having family that takes care
of you are signiﬁcant factors inﬂuencing a patient’s WTP.
Conclusions: Patients would like to pay less than the actual price of the
new medication for their lung cancer. Thus government and health poli-
cymakers should consider the ability to pay when making their decision
regarding the coverage of new drugs.
Keywords: burden of illness, cancer, contingent valuation method, health-
care costs, health care.
Background
Lung cancer is a major cause of cancer mortality the world over
[1,2]. Since 1982, lung cancer has been the second leading cause
of cancer mortality for males and the leading cause of cancer
mortality for females in Taiwan [3,4]. Between 1979 and 2002,
age-standardized lung cancer mortality rates per 100,000 per
year in Taiwan have increased sharply, from 16.13 to 38.38
among men, and from 6.41 to 19.63 among women [5]. In
addition, the female to male ratio of lung cancer patients was
higher than the average global ratio, and the cause remains
unclear [6]. Worldwide, over one million people die of lung
cancer each year. In the United States, lung cancer is the most
common cause of cancer deaths in both sexes [7,8], and mortality
rates in women have risen 500% since 1950 [9]. In the European
Union countries, although age-standardized mortality rates have
decreased for most cancer sites, lung cancer mortality rates have
risen signiﬁcantly in women [10].
The prognosis of lung cancer is poor, and according to the
reports from Western countries, the overall 5-year survival rate is
only 12% to 15% [2]. The high proportion of disseminated
disease and poor prognoses in these patients has justiﬁed the
continued efforts at developing new therapy options. Given the
rising rates of cancer prevalence, the inﬂuence of treatment
guidelines and quality-of-care initiatives, and the increasing focus
on treatment reimbursement by the National Health Insurance
(NHI), it has become more important than ever to elucidate the
costs associated with disease progression to better understand the
value of extending progression-free survival time.
Taiwan’s national health insurance (NHI) program is a
government-run mandatory single payer system, and was imple-
mented in 1995. By 2005, more than 99%of Taiwan’s population
was covered by the program. The NHI program provides com-
prehensive coverage, low copayment, freedom to choose any
provider, including inpatient care, ambulatory care, laboratory
tests, prescription drugs and certain nonprescription drugs, dental
services, traditional Chinese medicine, day care for persons with
mental illness, home care, and certain preventive services. Bed
capacity is distributed evenly across ownership types, 35% in
public hospitals, 35% not-for-proﬁt (NFP), and 30% for-proﬁt
(FP).
A copayment is required for ambulatory care, inpatient care,
and pharmaceuticals. Nevertheless, services for catastrophic dis-
eases, child delivery, and preventive health care, as well as
medical services offered in speciﬁc mountain areas or on offshore
islands, for low-income households, and for veterans, are exempt
from the copayment. “Catastrophic diseases” include cancer,
chronic mental illness, end-stage renal disease, and congenital
illness. For inpatient care, NHI only covers a three-bed hospital
room, and patients must pay the difference if they wish to
upgrade to a two-bed hospital room or a single-bed hospital
room.
The contingent valuation method (CVM) was developed as a
method of eliciting WTP. The CVM was originally a method for
measuring the beneﬁts of pure public goods and services without
markets, such as environmental goods. The theory of this meth-
odology is based on welfare economics, which can quantify the
economic value of health-care services from the consumer’s point
of view [11,12]. According to welfare economics, the beneﬁt to
an individual of a service or an intervention is deﬁned as that
individual’s maximum willingness to pay (WTP) for the service
or intervention. Over the past few decades, a considerable
number of health-care studies have been conducted using the
CVM, and the validity and reliability of the CVM has been
conﬁrmed repeatedly.
The dichotomous choice format involves a binary question to
a given price, and has been advocated by the NOAA panel
protocol on the CVM [13]. This elicitation method can be sta-
tistically highly inefﬁcient in that vastly larger numbers of
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observations are required to identify the underlying distribution
of resource values with any given degree of accuracy. In an effort
to extract more information from the respondents, Carson et al.
[14] proposed a dichotomous choice with “follow-up question.”
Here, respondents are provided with an immediate follow-up
question with either raised or lowered bids depending on the
response to the initial bids. Hanemann et al. [15] used
maximum-likelihood models to analyze dichotomous choice
with follow-up data, and showed that offering follow-up ques-
tions can increase the statistical efﬁciency in an estimation.
A variant of this method is the double-bounded format, in
which two successive binary questions are put to the subject,
with a second price conditioned on the responses to the ﬁrst
price. If the respondent answers “yes” to the ﬁrst question, then
the dollar amount is doubled, and the question is asked again. If
the respondent then answers “no,” then we are able to abound
WTP between the dollar amounts. If the respondent initially
answers “no,” then the dollar amount might be halved and the
question is asked again. Respondents end up in four groups:
“yes, yes,” “yes, no,” “no, yes,” and “no, no.” The beneﬁt of the
follow-up question is that analysis of these data substantially
reduces the variance of the average willingness to pay estimate.
The double-bounded dichotomous choice CV model is more
efﬁcient and provides more improved statistical information than
the single bounded model [15–17].
The purpose of this study was to use the contingent valuation
method to elicit the willingness of lung cancer patients to pay for
medication that provides a cure and to elucidate the factors
affecting WTP. The payment vehicle of this study was an extra
monthly premium to be able to receive the new technology
medication. A double-bound dichotomous choice method was
used to estimate the monetary value a patient placed on a novel
medication.
Materials and Methods
Patient Recruitment and Study Design
Patients with a diagnosis of lung cancer and aged 18 or older
were recruited. All patients were referred to us when they visited
their physicians from the chest department at the Taipei Veterans
General Hospital or the Kaohsiung Veterans General Hospital
between February 2003 and July of 2004. The physicians
explained the study purpose to their patients before referring
them to the interviewers. If the patients were not willing to take
part in the study, the physician would respect their decisions.
Patients who were unaware of their own medical condition were
excluded from participating. This study was approved by the IRB
board of both medical centers. Written informed consent was
obtained from all participants prior to conducting a face-to-face
interview.
Patients were interviewed in a secluded interview room by a
trained research nurse after their routine consultation. The
assessment was carried out using a battery of questionnaires,
including sociodemographics, WTP questions, and EQ-5D. The
EQ-5D, a ﬁve-dimensional (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression) health status measure
designed by the EuroQol group, is a generic, preference-based
health-related quality of life (HRQoL) questionnaire. EQ-5D
questionnaire has been widely validated and used to measure
cancer patients’ health-related quality of life [18]. During the
interview, the research nurse, one at each study site, read the
questionnaires to the patients and recorded their answers. These
research nurses also assessed the patients using the Karnofsky
Performance Scale (KPS), and patient clinical information was
obtained from their attending doctors.
The KPS [19] was used to assess the patients’ ability to carry
out activities of daily living. It is rated on a scale of 0–100, in steps
of 10, with higher scores representing a better functional status.
The KPS has good predictive validity [20], satisfactory interrater
reliability, and sufﬁcient construct and predictive validity [21].
Questionnaires
As in many other CV studies, this study included three kinds of
questions: the CV questions, the respondent’s socio demographic
variables, and validity checking questions. The bid vector was
selected by accounting for the results of the pretest survey. A
pretest pilot survey was conducted to revise any misinterpreta-
tion of the questions and to identify the bid vector that should be
used in the ﬁnal study. Extra monthly premium was used as the
payment method. The method of elicitation used in this study
was a double-bound question backed by an open-ended question.
It took on average 20–30 minutes to complete the interview. The
CV questions started with a scenario description that described
the deﬁcit of Taiwan’s National Health Insurance. The scenario
was described as follows.
The health insurance system in Taiwan is governed by the
Bureau of National Health Insurance (BNHI). It provides com-
prehensive health-care services for all of Taiwan’s citizens, with a
low registration fee and copayment, as well as a monthly
premium. Nevertheless, the BNHI is facing ﬁnancial difﬁculties
and is in danger of failure. Therefore, the BNHI is planning to
strictly control the usage of expensive new medications and its
coverage, which means that you have to pay for these medica-
tions with your own money.
Assume a novel medication would be available now, that
could free of your lung cancer and let you regain your health
again without side effects, but the BNHI will not pay for it.
Under such circumstance, in addition to your regular monthly
premium, would you be willing to pay an additional monthly fee
of NTD . . . (each respondent will be encountered an amount of
either NTD 500, NTD 700, NTD 1000, NTD 1500, NTD 2000,
NTD 2000, NTD 3000, NTD 4000, NTD 5000, NTD 6000,
NTD 7000, NTD 8000, or NTD 10,000) (1US$ = NTD 33
during the study period) to receive this new treatment for the rest
of your life?
If a respondent indicates a WTP the ﬁrst amount offered,
then a follow-up question with the new threshold at double the
ﬁrst one is asked. If the respondent is unwilling to pay the ﬁrst
amount offered, then the second threshold is reduced to about
half the original amount. The respondent only needs to answer
“yes” or “no” to these two questions. The interviewer also asks
the respondent to consider the situation that if they pay for the
new medication they may be short of money for other
expenses. An open-ended question follows the double-bounded
dichotomous question: What is the maximum price you
would be willing to pay per month for the remedy?
NTD_______(open).
The second WTP question is: If the government provides a
voluntary additional insurance of 1-year cover for hospitaliza-
tion, in which any expenses not covered by the current national
health insurance are fully paid until discharge. Are you willing to
pay an additional NTD_______(one of 2000, 3000, 4000, 5000,
6000, 7000, 8000, 10,000) per year for the premium for this
additional insurance?
If the answer is yes, then the question is asked again with the
premium doubling; otherwise, it is halved. An open-ended ques-
tion then follows the double-bounded dichotomous question:
How much is the maximum you are willing to pay for the
premium per year? NTD_______(open).
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Statistical Methods
The patients’ WTP for a new cure is assumed to be a function of
their socioeconomic and health status variables. The independent
variables for predicting the WTP includes sex, marital status,
religion, education, employment status, and monthly disposable
income. According to the economic theory, income is the single
most important factor that will inﬂuence patients’ WTP. The
EQ-5D was used to measure the patients’ health-related quality
of life. It is assumed that the worse the patient’s health status; the
more that patient would like to pay to be free of their illness. It
is also assumed that patients who live together with family would
like to pay for relieving the family caregiver from his/her physical
and spiritual burden. Nursing assistants and dietary supplements
were used to serve as proxies of patient’s ability to pay.
Interval regression and multiple linear regression methods
were used to estimate the mean WTP and to explore the inﬂuence
of independent variables on the referendum data. The indepen-
dent variables were selected based on the economic theory and
relevant knowledge including the WTP, sex, age, marital status,
education, religion, job status, health status, income, family care,
nursing assistant, dietary supplement and smoke. The elicitation
approach is illustrated in the following ﬁgure. The study esti-
mated the mean WTP using maximum likelihood methods based
on the “intreg” procedure with a robust error estimation by
STATA 8.1 (StataCorp, College Station, TX, 2003).
The double-bounded model generated interval censored data
on WTP, which was analyzed using survival analysis. The present
study used the interval censoring concept to measure patients’
WTP for the new hypothetical medication. The possible answers
to the double-bound dichotomous choice questions were classi-
ﬁed into four patterns pyy, pyn, pny, and pnn: “YES” to both the
ﬁrst and second question (YY); pyn “YES” to the ﬁrst question,
and “NO” to the second, higher value (YN); pny “NO” to the
ﬁrst value, and “YES” to the second, lower value (NY); and pnn
“NO” to both the ﬁrst and second value (NN).
Results
Demographic Characteristics
The demographic characteristics and health status of respondents
were showed in Table 1. In total, 294 patients completed the
interview. There were more males respondents than female
respondents (74.1% vs. 25.9%). Most of the respondents were
either married or had partners (83.0%). Most respondents
were religious; 52.0% were Buddhist or Taoist, and 10.5% were
Christians.More than half the respondents had an education level
lower than junior high school, and only 20% of the respondents
had a college education. About 80% of the respondents were
currently unemployed. Half of the respondents (55.9%) had a
monthly disposable income less than NTD 20,000; 33.9% had a
monthly income between NTD 20,000 and NTD 49,999; 2.4%
had a monthly income of more than NTD 100,000. The mean age
of the respondents was 66.5 years old, and the mean number of
their immediate family members was 3.8. Their health status
measured by the EQ-5D was 0.697 in terms of EQ-5D index and
65.92 in terms of EQ-5D value. Theirmean score of KPSwas 81.1.
Single-Bound WTP
Table 2 shows the willingness of lung cancer patients to pay an
extra monthly premium t obtain new or experimental medica-
tion, if it would return their health. The bids ranged from NTD
500 to NTD 10,000 per month. Each patient was sequentially
offered one bid (ranging between NTD 500 and NTD 10,000 per
month). As to the lowest bid of NTD 500, 88.5% of the respon-
dents were willing to pay that price. The percentage of WTP went
down as the bid values increased. Nevertheless, at the highest bid
of NTD 10,000, there were still 23.1% of the respondents that
were willing to pay this extra monthly premium. Figure 1 shows
the demand curve of the WTP for new medication.
Table 1 Demographic characteristics and health status of the
respondents
Characteristics N % Accumulate %
Sex
Male 217 74.10 74.10
Female 76 25.90 100.00
Marital status
Single 20 6.80 6.80
Married or with partner 244 83.00 89.80
Divorced or separate 7 0.00 92.20
Widower 23 7.80 100.00
Religion
No 109 37.10 37.10
Buddhism or Taoism 153 52.00 89.10
Christianity 31 10.50 99.70
Others 1 0.30 100.00
Education
Primary or less 136 46.70 46.70
Junior high school 41 14.10 60.80
Senior high school 56 19.20 80.10
College 54 18.60 98.60
Postgraduate 4 1.40 100.00
Employment status
Employed 58 19.90 19.90
Unemployed 234 80.10 100.00
Monthly disposable income
<20,000 NTD 160 55.90 55.90
20,000~49,999 NTD 97 33.90 89.90
50,000~79,999NTD 21 7.30 97.20
80,000~99,999 NTD 1 0.30 97.60
100,000 NTD 7 2.40 100.00
Cancer stage
I 53 18.00 18.00
II 12 4.10 22.10
IIIa 16 5.40 27.50
IIIb 22 7.50 35%
IV 42 14.30 49.30
Missing 149 50.70 50.70
Variables No. Mean SD
Age 290 66.5 12.3
Lives together with family 293 3.8 2.2
EQ-5D value 288 0.697 0.361
EQ-5D vas 292 65.92 17.7
KPS 264 81.1 19.9
NTD, New Taiwan dollar; EQ-5D, a ﬁve-dimensional (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression) health status measure developed by the EuroQol
group; KPS, Karnofsky Performance Status.
Table 2 Patients’ WTP for a new medication (ﬁrst bid)
Monthly WTP($)
Yes No Total
No. % No. % No. %
500 23 88.46 3 11.54 26 10.74
700 16 76.19 5 23.81 21 8.68
1,000 21 80.77 5 19.23 26 10.74
1,500 18 69.23 8 30.77 26 10.74
2,000 16 69.57 7 30.43 23 9.50
3,000 14 66.67 7 33.33 21 8.68
4,000 22 70.97 9 29.03 31 12.81
5,000 9 42.86 12 57.14 21 8.68
6,000 9 52.94 8 47.06 17 7.02
8,000 8 47.06 9 52.94 17 7.02
10,000 3 23.08 10 76.92 13 5.37
Total 159 83 242
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Double-Bound WTP
After the ﬁrst bid, the respondent was offered a second bid which
value depended on the answer to the ﬁrst bid. If the respondent
answered “yes” to the ﬁrst bid, then the second offered bid was
doubled, otherwise the second bid price was halved. Our results
showed that the percentages of those who would like to pay for
both bids decreased if the bid values increased (Table 3). The
percentage of patients who answered “yes” for the two lower
bids was 72.0%, and it was 4.0% for those who both answered
“no.” The percentage of patients who answered “yes” for the
two higher bids was 15.4%, and it was 53.9% for those who
answered “no” to both. The results also showed that the per-
centage of respondents who gave the same answer for both bids
(yes, yes or no, no) was more than 70%, except for NTD 1500
and NTD 6000 as the ﬁrst bids. For the ﬁrst bid of NTD 1500,
the percentage of the same answer was 60%, and for the ﬁrst bid
of NTD 6000, the percentage of the same answer was only
47.1%. This shows that patients ﬁnd it difﬁcult to make a deci-
sion in this price range.
Regression Analyses
Table 4 shows the WTP for new medication by the double-bound
interval regression and open-ended linear regression. Gender,
religion, income, family care, and KPS score are signiﬁcant
factors. Compared with male patients, female patients show a
signiﬁcantly positive willingness than male patients to pay an
extra monthly fee for obtaining the new lung cancer medication.
Christian patients are signiﬁcantly more willing to pay compared
with nonreligious patients. The logarithm of monthly household
income is a highly signiﬁcant positive factor, which is consistent
with the economic theory. Patients, who have family around to
take care of, show a signiﬁcant willing to pay as compared with
those who do not have. Health status as measured by the KPS
showed a negative inﬂuence on patients’ WTP. In other words,
the healthier the patients were (higher KSP scores), the less they
wanted to pay for a new treatment. The maximum WTP esti-
mated by interval regression was NTD 7416 (6314).
The open question result was analyzed by multiple log-linear
regressions. The F test of the multiple repression was signiﬁcant
(P < 0.0005). In this linear regression model, except religion,
other signiﬁcant factors are the same as the previous interval
regression. The estimated mean WTP was NTD 7032 (5356),
which is also similar to the result by interval regression.
Table 5 shows the interval regression of the WTP for supple-
mentary hospitalization insurance. The logarithm of monthly
household income is a highly signiﬁcant positive factor. Health
status as measured by the KPS also showed a negative inﬂuence
on patients’ WTP. In other words, the healthier the patients were,
the less they wanted to pay for a new treatment. The maximum
WTP estimated by interval regression was NTD 3089 (4962).
Discussion
Since 1999, lung cancer has replaced liver cancer as the leading
cause of cancer death in Taiwan [22]. The management of lung
cancer has changed signiﬁcantly over the last 10 years. New
diagnostic tools and medications have emerged, and these have
led to changes in the existing medical treatment paradigm [23].
The continuously increasing health-care cost of lung cancer in
developed countries is a reason for serious concern regarding the
economics of treatment and disease management [24,25]. In
Taiwan, the policy of BNHI’s new drug reimbursement has
resulted in BNHI being in debt. Nevertheless, few studies have
investigated this issue. Our study provides preliminary results on
patients’ WTP for their lung cancer treatment.
Our results showed that on average, patients would like to
pay NTD 7416  6314 (double-bounded dichotomous choice
questions) or NTD 7032  5355 (open-ended question) monthly
for an effective new medicine to treat their lung cancer. The result
from the interval regression and the follow-up open question all
showed that those who have family around to take care of the


















Figure 1 Patients’ WTP for a new medication.
WTP, willingness to pay.
Table 3 Patients’ WTP for a new medication (double-bounded)
WTP (NT$)
NO.
YY YN YY (%) YN (%)
First bid (second bid) NY NN NY (%) NN (%)
500 (250, 1,000) 25 18 4 72.00 16.00
2 1 8.00 4.00
700 (350, 1,400) 20 12 3 60.00 15.00
0 5 0.00 25.00
1,000 (500, 2,000) 26 18 3 69.23 11.54
3 2 11.54 7.69
1,500 (750, 3,000) 25 12 6 48.00 24.00
4 3 16.00 12.00
2,000 (1,000, 4,000) 23 12 4 52.17 17.39
2 5 8.70 21.74
3,000 (1,500, 6,000) 20 9 4 45.00 20.00
0 7 0.00 35.00
4,000 (2,000, 8,000) 31 15 7 48.39 22.58
2 7 6.45 22.58
5,000 (2,500, 10,000) 21 6 3 28.57 14.29
3 9 14.29 42.86
6,000 (3,000, 12,000) 17 5 4 29.41 23.53
5 3 29.41 17.65
8,000 (4,000, 16,000) 17 6 2 35.29 11.76
2 7 11.76 41.18
10,000 (5,000, 20,000) 13 2 0 15.38 0.00
4 7 30.77 53.85
Total number 238
WTP, willingness to pay.
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patients would like to pay more for the new medication. Family
support is an important factor for the patients to cope with the
disease. This is especially true in the Chinese culture.
In this study, we assumed that the double-bounded question-
naire provided a larger variety of information, which included
the censor data, and thus provided a more precise estimation. We
chose the double-bounded questionnaire design and used the
interval regression to estimate the mean value of a patient’s WTP
in reference to Hannemann [15] and Alberini [26], who found
that the double-bounded dichotomous choice CV model is sta-
tistically more efﬁcient and is a preferable method to the single
bid dichotomous model speciﬁcations.
Our results show that a patient’s maximum WTP for an
effective new medicine is much lower than the cost of current
new medications, such as Tarcevas at NTD3000 per pill, costing
NTD60,000 to 90,000 per month. The National Health Insur-
ance in Taiwan currently only reimburses Tarcevas as a third-line
medication. For those who would like to use it as a ﬁrst-line
medication, they will have to pay for it out of their own pocket.
Hence, few patients can afford it. Hideo [27] suggested that
government should enforce a safety net for the low-income group
to reduce their ﬁnancial burden. The health-care expenditure is
currently around 6.0% of the GDP [28] in Taiwan. Unless it
increases premiums or the copayment, NHI will be unable to pay
for all the effective new treatments. It is suggested that a prompt
economic evaluation of the lifetime cost and effectiveness of any
new medication is needed for Taiwan’s policymakers.
Reliability andValidity
To enhance the validity of a CV study, Mitchell and Carson [29]
stressed that the key scenario elements must be understandable,
meaningful, and plausible. That is, the WTP questions must be
clear and unambiguous, respondents should be familiar with the
commodity to be valued, and respondents should have had prior
valuation and choice experience with respect to consumption
levels of the commodity. Prior to ﬁnalizing the questionnaire, we
conducted pilot studies to modify the bid values and contents of
the questionnaire to make sure that the language and content
Table 4 Factors inﬂuencing a patient’s willingness to pay (WTP) for a new medication (double-boundWTP interval regression; open-endedWTP linear
regression)
WTP new medication Interval regression Linear regression
Parameter Estimate Standard error z P > z Estimate Standard error t P > t
Intercept -11.9216 4.5797 -2.60 0.009 -0.7925 2.79379 -0.28 0.777
Sex (female) 0.8568 0.4170 2.05 0.040 0.68898 0.26735 2.58 0.011
Age 0.0085 0.0139 0.61 0.541 0.00931 0.00961 0.97 0.334
Marriage (married) 0.2768 0.3553 0.78 0.436 0.1609 0.26255 0.61 0.541
Religion (ref. = non)
Buddhism or Taoism -0.2764 0.2821 -0.98 0.327 -0.2073 0.19943 -1.04 0.3
Christ or Catholicism 1.2389 0.5850 2.12 0.034 0.11726 0.35245 0.33 0.74
Educational (ref. primary)
Junior or senior high -0.3059 0.3129 -0.98 0.328 -0.0626 0.22927 -0.27 0.785
College education 0.0063 0.4418 0.01 0.989 0.3572 0.2981 1.2 0.233
Income 2.0449 0.4503 4.54 <0.000 0.79237 0.27397 2.89 0.004
Job (has) -0.2050 0.3648 -0.56 0.574 0.38946 0.26723 1.46 0.147
Family care 0.7035 0.3071 2.29 0.022 0.599 0.21429 2.8 0.006
Nursing assistant 5.2266 272.8689 0.02 0.985 -0.8216 0.87853 -0.94 0.351
Dietary supplement 0.4913 0.2791 1.76 0.078 0.14171 0.19529 0.73 0.469
kps -0.0279 0.0080 -3.48 0.001 -0.0097 0.00548 -1.77 0.08
eq5dvalue -0.1580 0.0952 -1.66 0.097 -0.1003 0.07337 -1.37 0.174
Smoke 0.1048 0.0583 1.80 0.072 0.05467 0.03916 1.4 0.165
/lnsigma 0.330246 0.102313 3.23 0.001
sigma 1.39131 0.142349
Number of obs = 195 Number of obs = 162
LR chi2(15) = 65.33 F(15, 146) = 2.90
Prob > chi2 = 0 Prob > F = 0.0005
R2 = 0.2297
Adj. R2 = 0.1505
Mean WTP SD Min Max Mean WTP SD Min Max
7,416.035 6,313.579 -1,373.6 48,579 7,032.76 5,355.56 -1,850.1 24,654.8
Table 5 Factors inﬂuencing a patient’s willingness to pay (WTP) for a
supplementary admission insurance (interval regression)
Parameter Coef. Std. Err. z P > z
Intercept 1.8551 3.6316 0.51 0.609
Sex (female) 0.3566 0.3546 1.01 0.315
Age -0.0019 0.0126 -0.15 0.881
Marriage (married) 0.1966 0.3380 0.58 0.561
Religion (ref. = non)
Buddhism or Taoism -0.1668 0.2565 -0.65 0.515
Christ or Catholicism 0.0736 0.4452 0.17 0.869
Educational (ref. Primary)
Junior or senior high -0.1127 0.2962 -0.38 0.704
College education 0.1753 0.3585 0.49 0.625
Income 0.9131 0.3589 2.54 0.011
Job (has) 0.1709 0.3357 0.51 0.611
Family care -0.3766 0.2762 -1.36 0.173
Nursing assistant 0.4916 0.9785 0.5 0.615
Dietary supplement -0.3560 0.2495 -1.43 0.154
kps -0.0305 0.0067 -4.52 0
eq5dvalue -0.1462 0.0913 -1.6 0.109
Smoke -0.0612 0.0502 -1.22 0.222
/lnsigma 0.2722 0.1050 2.59 0.01
sigma 1.3128 0.1379
Number of obs = 196
LR chi2(15) = 63.55
Prob > chi2 = 0
Mean SD Min Max
Mean WTP 3088.5 4962.423 6.1819 10.793
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were reasonable and easily understood. In addition, our respon-
dents were lung cancer patients, and thus they were well
informed regarding the value of the commodity in question.
Construct validity should be tested in WTP studies. One logic
of construct validation is to determine the theoretical construct
[30]. In the regression analysis, theoretic validity can be gauged
by regressing the WTP amount on a set of theoretical relevant
predictor variables. The size and sign of the estimated coefﬁcients
are then examined to determine theoretical consistency. Our
results showed that income is a signiﬁcant positive factor that
inﬂuences a patient’s WTP, which is consistent with the economic
theory [30]. Nevertheless, our estimation may be underesti-
mated. It is possible that the WTP value seen in a hypothetical
situation is lower than the WTP in a real situation. General
criticisms of CVM include the fact that WTP differs from the
actual payment [12,31], and that the WTP is not a monetary
value but only a sense of satisfaction (so-called warm glow) when
paying [32]. Another risk is the so-called “strategic bias” [12].
This refers to the tendency of individuals in a survey avoiding
giving any responses that may be detrimental to them. As nation-
wide compulsory health insurance is completely accepted in
Taiwan, those citizens who believe that the cost of medical ser-
vices should be the total responsibility of the government may
therefore be psychologically resistant to expensive medical
copayment, and this may have reduced the WTP.
Limitation
In this study, all the patients were referred by their physicians.
The physicians explained the study purpose to the patient and
then referred that patient to the interviewers immediately after
that patient’s routine consultation. For catastrophic disease,
patients were more loyal to their doctors. Hence, the refusal rate
was very low (<10%); we did not conduct analyses for those who
were not included in the study. A sample size estimation was also
not conducted before we started the data collection. Neverthe-
less, as a total of 294 patients completed the interview; the
sample size is larger than the estimated size of a = 0.05 and
power = 0.8. The physicians recruited patients sequentially and
only excluded those whose diagnoses were as yet not conﬁrmed.
Because the respondents that were interviewed were from two
major medical centers located in the north and south of Taiwan,
respectively, and they were interviewed during a speciﬁc period of
time, the results of our study may not be generalizable to the
entire population of Taiwan. Regarding the reliability, to the best
of our knowledge, only two studies, Bryan et al. [33] and Skjold-
borg et al. [34], investigated the reliability over time for a con-
tingent valuation study. Both studies show a high level of
reliability. In our study, we conducted a pilot study; however, the
reliability was not tested. Hanemann et al. [15] demonstrated
that the double-bound approach leads to more efﬁcient welfare
measures because it requests more information from the respon-
dent. Nevertheless, a disadvantage of this approach is that the
responses to the follow-up questions may lead to WTP estimates
that differ from the WTP estimates from the ﬁrst valuation ques-
tion [17] In other words, double-bound questions may be prone
to a form of starting point bias.
Conclusion
In Taiwan, lung cancer has great impact on both the value of
productivity and life lost because of both its incidence and mor-
tality rate. The increasing health-care cost of lung cancer treat-
ment has resulted in many debates on the issue of new drug
reimbursement in Taiwan’s National Health Insurance. Our
study shows that patients would like to pay less than the actual
cost of these new medications. Government and health policy-
makers should consider the ability to pay when making their
decision to cover or not to cover new medications.
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